ROS1 rearrangements in lung adenocarcinoma : prognostic impact, therapeutic options and genetic variability

BACKGROUND: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients

Bibliographic Details
Published in:Oncotarget, Vol. 6, No. 12 (2015), p. 10577-85
Main Author: Scheffler, Matthias
Other Involved Persons: Schultheis, Anne ; Teixido, Cristina ; Michels, Sebastian ; Morales-Espinosa, Daniela ; Viteri, Santiago ; Hartmann, Wolfgang ; Merkelbach-Bruse, Sabine ; Fischer, Rieke ; Schildhaus, Hans-Ulrich ; Fassunke, Jana ; Sebastian, Martin ; Serke, Monika ; Kaminsky, Britta ; Randerath, Winfried ; Gerigk, Ulrich ; Ko, Yon-Dschun ; Krüger, Stefan ; Schnell, Roland ; Rothe, Achim ; Kropf-Sanchen, Cornelia ; Heukamp, Lukas ; Rosell, Rafael ; Büttner, Reinhard ; Wolf, Jürgen
Format: electronic Article
Item Description:Date Completed 14.03.2016
Date Revised 21.02.2019
published: Print
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description:Online-Ressource
QR Code: Show QR Code